Original Publication Date: >1 March, 2014
Publication / Source: Pain Management
Authors: Michail Vikelis, Dimos D Mitsikostas & Alan M Rapoport
We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic transdermal system (Zecuity®, NuPathe Inc., PA, USA), recently approved for the acute treatment of migraine with or without aura in adults, by the US FDA. This transdermal system utilizes a low-level electrical current to deliver sumatriptan transdermally and circumvents the GI tract.